Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.14 by 78.57 percent. This is a 79.84 percent decrease over earnings of $1.24 per share from the same period last year. The company reported quarterly sales of $39.663 million which beat the analyst consensus estimate of $33.572 million by 18.14 percent. This is a 53.14 percent increase over sales of $25.900 million the same period last year.